Suresh Gupta
Biotech, long-term horizon, deep value, event-driven

Armed With 4-Antibody Acquisition, Agenus Returns To Melanoma 8 Years Later

The Agenus (NASDAQ:AGEN) saga just keeps getting more interesting with the twists and turns reaching back through time. My first article on the company back in August chronicles its history twenty years back, with special focus on Prophage, then called Oncophage, the company's heat shock protein [HSP] cancer vaccine platform. As a quick review, Prophage makes use of HSP's as an "antigen mold," so to speak, which allows immune cells called dendritic cells to pick up the antigens of a tumor from those HSP proteins which fold themselves around the tumor antigens.

Back in 2002, Agenus initiated a high profile phase 3 study of Prophage for melanoma. It failed miserably, not because Prophage failed to meet any endpoints,...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details